• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.08% Nasdaq Up0.33%

    More On IPSEY

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    Ipsen S.A. (IPSEY)

    -Other OTC
    13.84 Up 0.01(0.07%) 9:48AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Ipsen S.A.
    65, quai Georges Gorse
    Cedex
    Boulogne-Billancourt, 92650
    France - Map
    Phone: 33 1 58 33 50 00
    Fax: 33 1 58 33 50 01
    Website: http://www.ipsen.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:4,304

    Business Summary 

    Ipsen S.A. operates as a pharmaceutical company worldwide. It operates through two segments, Primary Care and Specialty Care. The company offers drugs in uro-oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and cardiovascular areas. Its products include Decapeptyl, a peptide formulation for injection for the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline, which is used primarily in the treatment of acromegaly and neuroendocrine tumors. The company also provides NutropinAq, a liquid formulation for use in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it offers Smecta, a natural clay-based drug for use in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan, an oral formulation, which is used for the treatment of age-related cognitive disorders. Further, the company provides Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl products. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Ipsen S.A.

    Key Executives 
     PayExercised
    Mr. Marc M.P. de Garidel , 57
    Chairman, Chief Exec. Officer and Member of Strategic Committee
    2.07MN/A
    Ms. Christel Bories , 51
    Deputy Chief Exec. Officer and Interim Exec. Vice-Pres of Technical Operations
    1.56MN/A
    Mr. Aymeric Le Chatelier , 46
    Chief Financial Officer, Exec. VP of Fin. and Member of Chairman's Committee
    N/AN/A
    Mr. Pierre Kemula ,
    VP of Corp. Fin., Treasury and Financial Markets
    N/AN/A
    Dr. Claude Bertrand , 53
    Chief Scientific Officer and Exec. VP of R&D
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.